Waste Management, Inc.

The filings describe a larger, more cash-generative company with a more complicated balance sheet. Operating cash flow rose to $6.04 billion in 2025 from $5.39 billion, and operating cash flow was 2.23 times net income, meaning reported cash generation is well above reported earnings. Total assets rose to $45.84 billion, liabilities eased to $35.84 billion from $36.31 billion, and equity increased to $9.99 billion from $8.25 billion. The Beneish M-Score is -2.745, which falls below -1.78 and is therefore not in the elevated manipulation-risk zone. That is a screening result only, not proof that the numbers are accurate. The Altman Z″-Score is 2.06, which sits in the grey zone between the distress and safe thresholds, so it signals some financial uncertainty rather than clear strength. The Piotroski F-Score is 5 of 6 computable signals, meaning five of the six computable checks of profitability, leverage and efficiency pass. Management's narrative emphasizes a people-first, technology-led strategy, a network of 257 landfill sites and 342 transfer stations excluding Stericycle, and a largest customer below 5% of revenues. The dividend increase from $0.825 to $0.945 per share, a 14.5% rise, marks the 23rd consecutive year of increases. Readers may want to read the Stericycle integration discussion and the segment results closely, since the headline growth depends heavily on that acquisition and net income did not follow revenue higher.

Catalyst.Management ties the business's momentum to five reportable segments: the East and West Tiers, Recycling Processing and Sales, Renewable Energy, and Healthcare Solutions. Revenue for 2025 was $25.2 billion, up 14.2% from $22.06 billion in 2024, and operating income rose to $4.31 billion from $4.06 billion. The filing presents Healthcare Solutions, built on the Stericycle acquisition completed in 2024, as a complementary platform in medical waste and secure information destruction. Management also says it has made substantial progress on leverage reduction, resumed share repurchases in February 2026, and expects to repurchase about $2.0 billion of shares during 2026 under a $3.0 billion authorization.

Hidden risk.Revenue grew faster than earnings. Net income fell from $2.75 billion in 2024 to $2.71 billion in 2025, and net income as a share of revenue dropped from about 12.5% to about 10.8%, even though operating income rose. The data provided does not explain the gap between operating and net income, so readers may want to examine the income statement and notes. The risk factors also flag Stericycle integration costs and benefits, diminishing landfill capacity, emerging-contaminant and extended producer responsibility rules, and impairment charges. Planned share repurchases and the stated goal of returning to targeted leverage compete for the same cash.